NEPHROS INC - Common Stock - $0.001 par value (NEPH)
CUSIP: 640671400
Q4 2021 13F Holders as of 31 Dec 2021
- Type / Class
- Equity / Common Stock - $0.001 par value
- Shares outstanding
- 10,630,964
- Total 13F shares
- 1,550,944
- Share change
- -149,553
- Total reported value
- $9,151,000
- Price per share
- $5.90
- Number of holders
- 11
- Value change
- -$931,227
- Number of buys
- 4
- Number of sells
- 6
Quarterly Holders Quick Answers
What is CUSIP 640671400?
CUSIP 640671400 identifies NEPH - NEPHROS INC - Common Stock - $0.001 par value in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 640671400:
Top shareholders of NEPH - NEPHROS INC - Common Stock - $0.001 par value (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Cowen Prime Advisors LLC |
13F
|
Company |
6.2%
|
660,150
|
$5,790,000 | — | 30 Sep 2021 | |
| Samjo Capital LLC |
13F
|
Company |
5.2%
|
550,000
|
$4,824,000 | — | 30 Sep 2021 | |
| BARD ASSOCIATES INC |
13F
|
Company |
2.2%
|
234,208
|
$2,054,000 | — | 30 Sep 2021 | |
| VANGUARD GROUP INC |
13F
|
Company |
0.96%
|
101,618
|
$891,000 | — | 30 Sep 2021 | |
| HighTower Advisors, LLC |
13F
|
Company |
0.52%
|
55,710
|
$488,000 | — | 30 Sep 2021 | |
| Daron Evans |
3/4/5
|
CEO Specialty Renal Products |
—
mixed-class rows
|
179,718
mixed-class rows
|
$351,795 | — | 24 May 2021 | |
| BLAIR WILLIAM & CO/IL |
13F
|
Company |
0.34%
|
36,249
|
$318,000 | — | 30 Sep 2021 | |
| BlackRock Finance, Inc. |
13F
|
Company |
0.17%
|
18,079
|
$158,000 | — | 30 Sep 2021 | |
| MORGAN STANLEY |
13F
|
Company |
0.13%
|
13,837
|
$121,000 | — | 30 Sep 2021 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.13%
|
13,424
|
$118,000 | — | 30 Sep 2021 | |
| ELKHORN PARTNERS LIMITED PARTNERSHIP |
13F
|
Company |
0.08%
|
8,500
|
$75,000 | — | 30 Sep 2021 | |
| OSAIC HOLDINGS, INC. |
13F
|
Company |
0.04%
|
4,569
|
$40,000 | — | 30 Sep 2021 | |
| SALEM INVESTMENT COUNSELORS INC |
13F
|
Company |
0.03%
|
3,500
|
$31,000 | — | 30 Sep 2021 | |
| Total Clarity Wealth Management, Inc. |
13F
|
Company |
0.01%
|
653
|
$6,000 | — | 30 Sep 2021 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0%
|
169
|
$1,000 | — | 30 Sep 2021 | |
| FMR LLC |
13F
|
Company |
0%
|
91
|
$1,000 | — | 30 Sep 2021 |
Institutional Holders of NEPHROS INC - Common Stock - $0.001 par value (NEPH) as of Q4 2021
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q4 2021 vs Q3 2021 Across Filers
| Investor | Q3 2021 Shares | Q4 2021 Shares | Share Diff | Share Chg % | Q3 2021 Value $ | Q4 2021 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
An asterisk sign (*) next to the price indicates that the price is likely invalid.